Clinical trial compliance triples with electronic diaries, says CRF

22 June 2008

Patient compliance to protocol in clinical trials using electronic diaries is more than three times that for paper-based trials, according to research released by CRF, a global provider of electronic Patient Reported Outcomes (ePRO). Accurate, timely and complete patient data improves the quality and reliability of patient reported data, the company says.

CRF's research also showed that pensioners are the most compliant demographic when using electronic reporting tools, dispelling the belief that technology negatively affects their compliance rating.

The trials, which were conducted on almost 30,000 subjects across 23 different therapeutic areas in 42 countries, also revealed geographic and gender differences where compliance to clinical trial protocol is concerned. Women were on average 13% more compliant than males and Indian subjects were the most compliant of all geographies, says CRF.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight